Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.69 |
| ▸ | IDO1 | P14902 | 7/20 | 0.61 |
| ▸ | TDO2 | P48775 | 3/20 | 0.61 |
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29437202 | 1.00 | EGFR (0.69) | EGFRIDO1TDO2GSK3BGLA | |
| SCHEMBL3201173 | 0.89 | EGFR (0.65) | EGFRIDO1TDO2HSD17B10MAPT | |
| Oxindole SCHEMBL1460829 | 0.86 | AHR (0.54) | EGFRIDO1TDO2GSK3BGLA | |
| SCHEMBL14555787 | 0.85 | IDO1 (0.57) | EGFRIDO1TDO2GSK3BMAPT | |
| SCHEMBL6925979 | 0.85 | IDO1 (0.57) | EGFRIDO1TDO2GSK3BMAPT | |
| SCHEMBL28573199 | 0.85 | IDO1 (0.64) | EGFRIDO1TDO2GSK3BHSD17B10 | |
| SCHEMBL5380593 | 0.83 | EGFR (0.70) | EGFRIDO1TDO2GSK3BMAPT | |
| SCHEMBL1388509 | 0.81 | EGFR (1.00) | EGFRIDO1TDO2GLAHSD17B10 | |
| SCHEMBL5879507 | 0.81 | EGFR (0.61) | EGFRIDO1TDO2GSK3BGLA | |
| SCHEMBL8998981 | 0.81 | EGFR (0.72) | EGFRIDO1TDO2GSK3BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4424365-A2 | PET FOOD COMPOSITIONS | Hill's Pet Nutrition, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| EP-4017281-B1 | PET FOOD COMPOSITIONS | HILLS PET NUTRITION INC (US) | 2024-08-28 | — | — | EP | claimed |
| CN-117683845-A | New use of small molecular substances for enhancing intestinal fatty acid absorption and screening method | 浙江大学 | 2024-03-12 | — | — | CN | claimed |
| CN-116794202-A | Screening and application of metabolic markers of rifampicin drug-resistant tuberculosis | 首都医科大学附属北京胸科医院 | 2023-09-22 | — | — | CN | claimed |
| US-11758928-B2 | Compositions and methods that modulate phosphorus or enzymes in a companion animal | Société des Produits Nestlé S.A. (CH) | 2023-09-19 | — | — | US | claimed |
| EP-3554258-B1 | COMPOSITIONS AND METHODS THAT MODULATE PHOSPHORUS OR ENZYMES IN A COMPANION ANIMAL | NESTLE SA (CH) | 2023-07-19 | — | — | EP | claimed |
| CN-114828648-A | Pet food compositions | 希尔氏宠物营养品公司 | 2022-07-29 | — | — | CN | claimed |
| EP-4017281-A1 | PET FOOD COMPOSITIONS | Hill's Pet Nutrition, Inc. (US) | 2022-06-29 | — | — | EP | claimed |
| WO-2021127701-A1 | PET FOOD COMPOSITIONS | HILL'S PET NUTRITION, INC. (US) | 2021-06-24 | — | — | WO | claimed |
| EP-3554258-A1 | COMPOSITIONS AND METHODS THAT MODULATE PHOSPHORUS OR ENZYMES IN A COMPANION ANIMAL | Société des Produits Nestlé S.A. (CH) | 2019-10-23 | — | — | EP | claimed |
| WO-2018109668-A1 | COMPOSITIONS AND METHODS THAT MODULATE PHOSPHORUS OR ENZYMES IN A COMPANION ANIMAL | NESTEC SA (CH) | 2018-06-21 | — | — | WO | claimed |
| US-20160331725-A1 | USE OF COMPOUNDS THAT ARE ABLE TO INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASE STATES ASSOCIATED WITH A REDUCED IGF-1 SERUM LEVEL IN HUMANS AND ANIMALS | VEIJLEN N.V. | 2016-11-17 | — | — | US | claimed |
| US-20150065366-A1 | Biomarkers for Bladder Cancer and Methods Using the Same | METABOLON, INC. | 2015-03-05 | — | — | US | claimed |
| EP-2776832-A1 | BIOMARKERS FOR BLADDER CANCER AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2014-09-17 | — | — | EP | claimed |
| WO-2013070839-A1 | BIOMARKERS FOR BLADDER CANCER AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-05-16 | — | — | WO | claimed |
| JP-4641942-B2 | — | — | 2011-03-02 | — | — | JP | claimed |
| US-20080194553-A1 | compounds that are capable of increasing the serum level of insulin-like growth factor 1 (IGF-1) for the preparation of a therapeutical composition,in the form of a food supplement, for the treatment of subjects suffering from serious fatigue and exhausting symptoms, burn-out and chronic fatigue syndrome | VEIJLEN N.V. (NL) | 2008-08-14 | — | — | US | claimed |
| EP-1670444-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | Veijlen N.V. (AN) | 2006-06-21 | — | — | EP | claimed |
| WO-2005039546-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | VEIJLEN N.V. (AN) | 2005-05-06 | — | — | WO | claimed |
| US-5849756-A | Pharmaceutical composition and method for modulating the immune reaction | CERBIOS-PHARMA SA (CH) | 1998-12-15 | — | — | US | claimed |